Softbank Vision Fund

SoftBank Vision Fund is the largest single pool of growth capital in technology, and its healthcare practice has become an increasingly defined part of the platform. Operated by SoftBank Investment Advisers from offices in Tokyo, London, Silicon Valley, and beyond, the Vision Fund deploys checks of twenty-five million dollars and up at Series C, Series D and beyond, and growth stages. For physician-founders building AI-native healthcare companies, the Vision Fund is the late-stage capital partner that has the balance sheet to lead nine-figure rounds, the global reach to support multi-geography commercialization, and the appetite to underwrite ambition in AI/ML in healthcare, digital health, and biotech that few peers can match.

The fund’s healthcare thesis sits inside its broader bet on AI as the defining technology shift. Vision Fund 2’s sector allocation includes roughly ten percent in healthcare, and within that allocation the team has concentrated on companies whose moats compound with data scale: drug discovery and development platforms, AI-enabled diagnostics, virtual care infrastructure, and biotech with unusual data assets. The firm targets companies that can become global category leaders, with criteria that explicitly include market potential, technology differentiation, scalability, leadership quality, strategic fit, and financial trajectory. Diligence is rigorous and benchmarked against the Vision Fund’s broader portfolio of more than three hundred fifty companies, including over one hundred thirty unicorns. The firm tends to lead, prices for category leadership, and supports outsized ambition with proportionally outsized checks. Founders raising small late-stage rounds will struggle to capture attention; founders building companies that intend to define a category at global scale are the natural target.

The healthcare portfolio reflects the thesis. Roivant Sciences received an eleven-hundred-million-dollar equity investment led by SoftBank Vision Fund, supporting the platform’s network of subsidiary therapeutics companies including Axovant, Myovant, Dermavant, Enzyvant, and Urovant. Karius, the infectious-disease liquid biopsy company, raised a one-hundred-sixty-five-million-dollar Series B led by Vision Fund 2 to scale its microbial cell-free DNA platform. Vir Biotechnology, focused on infectious disease therapeutics, was a Vision Fund 2 investment alongside Roivant. Tempus, the precision medicine and clinical data platform, has been backed by SoftBank Group capital. Biofourmis, the virtual care and AI-driven therapeutics company, raised a one-hundred-million-dollar Series C led by SoftBank in 2020. Together these names show the firm’s willingness to back AI-driven therapeutics platforms, infectious disease genomics, and digital therapeutics at scale.

Stage and check size place the Vision Fund firmly at the late stage. Twenty-five million dollars and up describes a floor; the fund regularly leads rounds of one hundred million dollars and well above. Series C and D-plus growth rounds, pre-IPO crossover, and significant follow-on are the modal investments. The firm reserves capital generously and is comfortable supporting a company across multiple rounds. Companies pursuing local-niche outcomes or modest growth are not a fit; companies with global ambitions, defensible technology, and the operating capability to deploy nine-figure capital efficiently are.

Decision-making sits with the SoftBank Investment Advisers team led by CEO Alex Clavel, who succeeded Rajeev Misra in 2024. Navneet Govil serves as Executive Managing Partner and CFO. Recent senior promotions include Managing Partners and Partners Michelle Aylott, Amanda Sanchez-Barry, Mike Guo, Hugh Manahan, Sarthak Misra, Max Ohrstrand, and Adam Westhead. The investment process involves senior sponsor engagement, structured diligence, and committee review. SoftBank Group provides additional strategic context across consumer technology, AI infrastructure, and global operations.

Warm-intro paths run through existing Vision Fund portfolio CEOs, the firm’s healthcare-active partners, leading global investment banks covering healthcare growth and crossover, and co-investors at earlier rounds in the company. The fund engages frequently with corporate development teams at large pharma, US health systems, and global technology partners; introductions from those relationships carry weight. Cold inbound is the slowest channel; structured introductions with prior diligence visible to the firm move materially faster.

Founders should approach the Vision Fund when their company has clear product-market fit, a credible global expansion plan, and capital needs that match the firm’s check size. Earlier-stage healthcare AI companies should not pursue the Vision Fund directly. Founders who bring a clear category thesis, evidence of platform leverage, and management capable of running a global late-stage business will find the firm an engaged and ambitious partner. Founders looking for a passive late-stage check will find the firm’s appetite for scale and operating involvement either welcome or uncomfortable; both founders and the fund are best served by clarity on this fit before signing.